Clinical Trial Update: 17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 clinical trial update evaluating 17α-hydroxyprogesterone caproate for reducing neonatal morbidity due to preterm birth in twin and triplet pregn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Preterm Birth

Drugs mentioned

• 17 α-hydroxyprogesterone caproate (17α-hydroxyprogesterone caproate)

Snippet

Sponsor: Obstetrix Medical Group | Conditions: Preterm Birth | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2012-11-07